TO REGISTER CLICK RUN FOR GOOD LOGO
The Greenhills Alois Run for Good is set for
Saturday, October 24, 2015
This is a 5K Run or 1 Mile Walk
Beginning time is 8:30AM
Race will be held at The Village of Greenhills
adjacent to The Greenhills Community Building
8 Enfield Street Cincinnati, OH 45218
Run for Good is held in conjunction with The Village of Greenhills Harvest Festival.
Proceeds will benefit The Alois Alzheimer Foundation, a 501(c)3, non-profit organization
Proud Sponsors of this event are:
CLEVELAND, Ohio — Researchers at the Cleveland Clinic are taking a small step forward in testing for the first time on people a promising treatment for Alzheimer’s disease—a cancer drug that rapidly removed the damaging protein implicated in the progression of the illness from the brains of mice in early trials at Case Western Reserve University.
Doctors at the Clinic’s Lou Ruvo Center for Brain Health in Las Vegas are recruiting patients with moderate Alzheimer’s for the first trial of the drug in human patients with the disease. The drug, called bexarotene (also known as its brand name Targretin), is approved by the Food and Drug Administration to treat cutaneous T-cell lymphoma, which is a cancer of the blood that affects the skin.
The Clinic researchers are building off the work of Case neurosciences professor Gary Landreth and his former graduate student, Paige Cramer, who is currently employed at pharmaceutical giant Merck & Co. Last year, Landreth and Cramer published a landmark paper in the journal Science, showing that bexarotene not only quickly cleared out a protein called amyloid beta, which is both deposited in sticky plaques and circulates in the brains of mice bred to mimic the Alzheimer’s condition, but also improved memory in those mice.
Read the full article…
A new discovery at the Yale School of Medicine has uncovered a key component to understanding and curing Alzheimer’s disease.
The neurofibrillary tangling and degradation of links between neurons characteristic of Alzheimer’s is the result of a long chain of protein interactions that has intrigued researchers for decades. Scientists at the Medical School have recognized a receptor called metabotropic glutamate receptor 5, or mGluR5, as the missing link in the chain of biological processes leading to Alzheimer’s disease. The findings on mGluR5 were published in the journal Neuron on Sept. 4.
To read full article…
Regular exercise may inhibit the effects of Alzheimer’s disease, according to ongoing research by Stefan Keslacy, an assistant professor of exercise science in the School of Education.
To read more…http://dailyorange.com/2013/02/professor-researches-link-between-exercise-and-alzheimers-disease/
Did you find this article helpful?